
Opinion|Videos|January 7, 2025
Addressing Challenges in BCG-Unresponsive NMIBC: Overview and Unmet Needs
Author(s)Max Kates, MD
Max Kates, MD, discusses how BCG-unresponsive non-muscle invasive bladder cancer patients historically faced limited treatment options beyond radical cystectomy, with significant unmet needs in preserving bladder function while effectively treating this aggressive disease.
Advertisement
Episodes in this series

- Would you please start by giving a brief overview of BCG-unresponsive NMIBC? Nonmuscle Invasive Bladder Cancer
- Prior to recent therapeutic innovations in the bladder space what challenges or unmet needs did you face when treating these patients?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5










